Chlamydia trachomatis is the leading cause of preventable blindness and bacterial sexually transmitted diseases worldwide. Plaque assays have been used to clonally segregate laboratory-adapted C. trachomatis strains from mixed infections, but no assays have been reported to segregate clones from recent clinical samples. We developed a novel shotgun cell culture harvest assay for this purpose because we found that recent clinical samples do not form plaques. Clones were strain-typed by using outer membrane protein A and 16S rRNA sequences. Surprisingly, ocular trachoma reference strain A/SA-1 contained clones of Chlamydophila abortus. C. abortus primarily infects ruminants and pigs and has never been identifi ed in populations where trachoma is endemic. Three clonal variants of reference strain Ba/Apache-2 were also identifi ed. Our fi ndings refl ect the importance of clonal isolation in identifying constituents of mixed infections containing new or emerging strains and of viable clones for research to more fully understand the dynamics of in vivo strain-mixing, evolution, and disease pathogenesis.
Increasingly, isolates representing single clones are needed for in vitro and in vivo research, including genomic, murine, and translational studies, to advance our understanding of chlamydial pathogenesis. Although a few studies have described methods for segregating clones of laboratory-adapted C. trachomatis clinical and reference strains (12, 15, 16) , none has clonally purifi ed all 19 C. trachomatis reference strains nor determined optimal methods to clonally segregate clinically mixed samples. Consequently, we modifi ed the plaque-forming assay of Matsumoto et al. (16) to segegrate clones from reference strains and developed a novel cell culture shotgun harvest assay to segregate viable clones from recent clinical samples because typical plaques do not form for most of these samples.
Our culture techniques coupled with outer membrane protein A (ompA ) and 16S rRNA sequencing identifi ed the constituents of mixed infections that represented new and emerging Chlamydiaceae strains and clonal variants in human disease. These results stress the importance of clonal isolation for these types of discoveries. Clonal isolates will also be essential for chlamydial research to ensure reproducibility of experiments among laboratories and to understand the dynamics of in vivo strain-mixing, evolution, and disease pathogenesis.
Materials and Methods

C. trachomatis Reference and Clinical Strains
We studied 19 C. trachomatis reference strains (A/ SA-1, B/TW-5, Ba/Apache-2, C/TW-3, D/UW-3, Da/ TW-448, E/Bour, F/IC-Cal3, G/UW-57, H/UW-4, I/UW-12, Ia/IU-4168, J/UW-36, Ja/UW-92, K/UW-31, L1/440, L2/434, L2a/TW-396, and L3/404) and 5 clinical strains, representing ompA genotypes G, F, H, Ja, and K (Table  1) . Reference strains were the original isolates. A/Har-13; Chlamydophila caviae, strain GPIC; Chlamydia muridanum, strain Nigg; Chlamydophila abortus, strain S26/3; and another seed stock of A/SA-1 were included for PCR amplifi cation analyses (see Preparation of Genomic DNA and Sequencing of ompA and 16S rRNA for Each Clone). Clinical strains were isolated from acute (Ja and K strains; no prior history of chlamydial STD) and persistent cervical strains (F, G, and H; same-ompA genotypes occurring in the same woman over several years despite antimicrobial drug therapy). Clinical samples were identifi ed by a unique identifi cation number with no link to patient names.
C. trachomatis Culture and Titration of Inclusion-Forming Units
Confl uent monolayers of McCoy cells were inoculated with reference and clinical strains by centrifugation at 550 × g for 1 h at 35°C. Cultures were maintained at 37°C and 5% CO 2 in chlamydial growth medium (CMGH), which contains minimal essential medium (MEM; Cellgro, Mannassas, VA, USA]; 10% fetal bovine serum (FBS; University of California, San Francisco [UCSF] Cell Culture Facility, San Francisco, CA, USA); 0.45% glucose solution (Cellgro); 20 mmol/L HEPES (UCSF Cell Culture Facility); 0.08% NaHCO 3 , 10 μg/mL gentamicin (MP Biomedicals, Solon, OH, USA); 25 μg/mL vancomycin (Acros Organics, Morris Plains, NJ, USA); 25 units/mL nystatin (MP Biomedicals), 375 μg/mL amphotericin B (PharmaTek, Huntington, NY, USA); 1 μg/mL cyclohexamide for 48 h and harvested as described (18, 19) . Inclusion-forming units (IFUs) were titrated after 30-48 h of growth, depending on the strain, by using chlamydial lipopolysaccharide (LPS)-specifi c monoclonal antibodies (LPS-MAbs; Virostat, Portland, ME, USA) (2,18).
Plaque Assay for Reference Strains and Clinical Samples
We modifi ed the plaque assay of Matsumoto et al. (16) by using low speed centrifugation at 550 × g and 6-well plates for infections, and 1-dram shell vials (Kimble Chase Inc., Vineland, NJ, USA) for propagation. To ensure detection of mixed infections, 1:3 and 1:1 ratios of IFUs for reference strains E/Bour and D/UW-3, and a 1:1 ratio for clinical strains F and G, were created for inoculation and harvest.
Reference and clinical strains were serially diluted in sucrose-phosphate-glutamine (SPG) (219 mmol/L sucrose; 3.82 mmol/L KH 2 PO 4 ; 8.59 mmol/L Na 2 HPO 4 ; 4.26 mmol/ L glutamic acid; 10 μg/mL gentamicin; 100 μg/mL vancomycin; 25 U/mL nystatin in distilled water, pH 7.4). Each 6-well plate contained dilutions from 1.25 × 10 6 IFUs in the 1st well to 1.25 × 10 IFUs on 60%-70% confl uent McCoy cell monolayers. Two 6-well plates were prepared identically per strain except that the second plate contained a glass coverslip in each well. After centrifugation, the inocula were removed and replaced with CMGH plus 1 μg/mL cyclohexamide and maintained at 37°C in 5% CO 2 .
At 24 h postinfection (p.i.), culture medium was aspirated, and wells were overlaid with initial agarose (IAO: 0.5% SeaKem ME agarose [BMA, Rockland, ME, USA]) in phenol red-free MEM (BioWhittaker, Walkersville, MD, USA); 10% FBS; 1 μg/mL cyclohexamide. Two milliliters of CMGH without cyclohexamide were added to the solidifi ed IAO. Medium was replaced every 4 days to optimize chlamydial growth.
Once small plaques formed by visual inspection at 7-12 days p.i., medium was removed, and fi nal agarose overlay (FAO: 0.5% SeaKem ME agarose in phenol red-free MEM; 10% FBS; 1/100 volume of 3% neutral red [SigmaAldrich, St. Louis, MO, USA]) was dispensed onto IAO. CMGH, without cyclohexamide, was added, and the plates were incubated for 12-24 h.
At 48 h, duplicate plates with coverslips were fi xed with methanol and stained with a fl uorescein isothiocyanate (FITC)-conjugated C. trachomatis LPS-MAbs (18) . Inclusions on each cover slip were counted to determine IFUs per milliliter per well and effi cacy of infection given the calculated IFUs inoculated for each well.
Plaques were visualized as a central area of cellular debris surrounded by viable infected cells with red staining of cytoplasm at the cell periphery (Figure 1 , panels A and C). Inclusion bodies and nonviable cells remained clear. Any plaque (≈1-2 mm) that was clearly isolated from another plaque, or appeared as a solitary plaque in a well, was se- 
*p.i.,.postinoculation; ompA, outer membrane protein A; -, no evidence for nucleotide substitution. †Represents an equal mixture of inclusion-forming units (IFUs) of each strain. ‡Represents a 3:1 mixture of IFUs of reference strains D/UW-3 and E/Bour. §Represents the plaques from the 1:1 mixture of D/UW-3 and E/Bour when both reference strains were found in 3 plaques. ¶Represents the plaques that were harvested from the wells with 10 -8 dilution. #Boldface denotes nonconservative amino acid substitution (17) .
lected. A blunt-ended transfer pipette was used to punch a hole ≈1-2 mm in diameter through the gels over the plaque. The contents were placed into a microcentrifuge tube containing CMGH, sonicated and added to shell vials containing McCoy monolayers for propagation. Centrifugation of shell vials at 2,400 × g for 1 h at 35°C was required to successfully grow each clonally segregated strain. Strains were propagated and purifi ed using gradient ultracentrifugation as previously described (2, (18) (19) (20) . The pellet was resuspended in SPG, and stored at -80°C.
Shotgun Harvest, Isolation, and Propagation of Single Clonal Populations for Clinical Strains
Because no visible plaques formed for the clinical strains, except for clinical H, the plates were inspected under 100× and 400× light microscopy. Wells were selected for our shotgun harvest as shown in the diagram (Figure 2 ).
Ten spots per well were numbered where the infections were observed under microscopy. Each spot was harvested (≈2-3 wells × 10 spots per well = 20-30 harvests) using a sterile, blunt-ended transfer pipette.
IAO and FAO were carefully removed, and the wells were stained using FITC-conjugated C. trachomatis LPSMAb (Virostat). Only harvested areas that corresponded to a confi ned group of infected cells with a clear margin from uninfected cells were selected, sonicated, inoculated, propagated in shell vials and fl asks purifi ed and stored as above. The original clinical samples were also independently propagated in shell vials as described previously (2, (18) (19) (20) for comparison with growth in the plaque assay.
Preparation of Genomic DNA and Sequencing of ompA and 16S rRNA for Each Clone
Purifi ed culture was used for genomic DNA extraction according to High Pure Template Preparation Kit package insert (Roche Diagnostics, Indianapolis, IN, USA). PCR was performed and reagents, thermocycling profi le, and sequencing were used according to previously described protocols (21). Table 2 (22) shows the primers used for PCR and sequencing to identify the strain-type of each clone. Multiple sequences were aligned by using MegAlign software (DNASTAR, Madison, WI, USA) and compared with public sequences (21, 23) . A variant was defi ned as having >1 nucleotide difference(s) from the sequence of the reference strain for either ompA or 16S rRNA genes. 
Phylogenetic Construction of ompA Nucleotide and Amino Acid Sequence Alignments
Nucleotide and amino acid alignments and phylogenetic analyses of the 19 reference strains and clonal variants were performed by using MEGA 3.1 (Center for Evolutionary Functional Genomics, Tempe, AZ, USA) as described (21, 23) . Briefl y, neighbor-joining trees were calculated using the Kimura 2-parameter model that assumes that nucleotide frequencies and rates of substitution do not vary among sites. For amino acids, neighbor-joining trees were calculated using the gamma distance model that considers the dissimilarity of substitution rates among sites. We used bootstrap analysis (1,000 replicates) to determine confi dence intervals for each branch.
Results
Plaque Formation by Reference C. trachomatis Strains Figure 1 , panel A, shows typical plaque formation for F/IC-Cal3. Higher inocula resulted in plaques that fused and, therefore, were not suitable for harvest. These fi ndings are similar to those of others who have used plaque-or focus-forming assays for clonal segregation of laboratoryadapted chlamydial strains (16, 24) . Table 1 shows the day p.i. that plaques were visualized and the number of isolated clones and nucleotide polymorphisms with respect to reference strain sequences. All reference strains formed mature plaques ≈1-2 mm in diameter. Experimentally mixed infections of D/UW-3 and E/Bour resulted in 13 D, 9 E and 3 D/E clones, and 9 D and 0 E clones. The 3 D/E clones were identifi ed as mixed based on electropherograms where 2 peaks were observed in a single nucleotide position that corresponded to D and E sequences for ≈20 nucleotide positions. These 3 mixed infections were further plaque-purifi ed as above and yielded single clonal populations of D or E, which validated our plaque assay for isolating clonal populations.
Detection of Clonal Populations of C. trachomatis Clinical Strains by Shotgun Harvest
The clinical strains Ja, K, F, and G showed no plaques, while persistent strain K showed signs of <0.5-mm plaques at 10 days p.i., and strain H showed typical plaques at 7 days p.i. A longer growth period up to 20 days p.i. did not result in distinct plaque formation for Ja, K, F, or G. Notably, the size of the inclusion body was much smaller for clinical strains than for reference strains. Figure  1 , panel E shows typical large inclusion bodies formed by reference F/IC-Cal3 compared with tiny and occasional medium-sized inclusion bodies at day 10 for persistent clinical strain F (Figure 1, panel F) . Similar results were observed for persistent clinical strains G and H when compared with respective reference strains. In contrast, acute clinical strains Ja and K had inclusion bodies that were intermediate in size (data not shown). When original clinical samples were propagated in shell vials, inclusions remained small and the rate of growth was similar as for the plaque assay.
Mixed clinical G and F strains yielded 12 G clones (92.31%), 1 F clone (7.69%), and no mixed clones based on sequencing. Figure 3 , panel A, represents 1 well after 10 random areas were harvested since no plaque was visible ( Figure 3, panel B) . Figure 3 , panel C, represents a microscope photo where chlamydial inclusions are diffi cult to visualize due to their small size. Figure 3 , panel D, is a fl uorescent image of Figure 3 , panel C, displaying small and medium-sized inclusion bodies.
Sequence Analyses of ompA and 16S rRNA C. trachomatis Clonal Populations
A total of 30 chlamydial ompA genotypes were identifi ed from the plaque assay and shotgun harvest based on sequence analyses using BLAST and MegAlign as we have described (21, 22) (Table 1) . Three reference strains showed mixed infections: Ba/Apache-2 with new Ba ompA genotypes, Ba 1 , Ba 2 , and Ba 3 (1 clone each), F/IC-Cal3 with F-III (5), L 2 /434 with L 2 ′ (9), and A/SA-1 with C. abortus S26/3 (25) , which were clonally segregated into 14 A and 4 C. abortus clones ( Table 1 ). All 4 C. abortus clones had the same sequences for ompA and 16S rRNA.
The C. abortus-specifi c primers (Table 2) were used to amplify another seed stock of A/SA-1, C. abortus (from our plaque assay), C. trachomatis strain A/ Har-13, and C. caviae and C. muridanum. For the C. abortus-specifi c PCR amplifi cation, only A/SA-1 and C. abortus samples were positive, while the rest were negative.
Phylogenetic Analyses of ompA C. trachomatis Reference and Clonal Populations
Phylogenetics of ompA nucleotide and amino acid sequence alignments were performed to evaluate divergence of 5 clonal variants of Ba/Apache-2 and F/IC-Cal3. The trees showed the clustering of the 5 clonal variants with their respective parental strains (Figure 4, panels A and B) .
Discussion
Plaque-and focus-forming assays have been developed to isolate individual clonal populations of reference strains of C. trachomatis (12, 15, 16) and Chlamydophila pneumoniae (24) . The fi rst methods for C. trachomatis used L (15) and McCoy cells (16) . More recently, fl ow cytometry has been used to segregate cells infected with C. trachomatis, C. caviae, and Chlamydia suis (12) . However, these techniques have focused on laboratory-adapted clinical and reference strains and have not used nonpropagated or nonlaboratory-adapted clinical samples.
The novel shotgun harvest assay that we developed was successful in segregating clonal populations of C. trachomatis strains and variants that were devoid of plaqueforming characteristics. Consequently, our method is an important advance in reliably detecting and purifying clonal isolates from clinical samples. We also modifi ed the plaque protocol of Matsumoto et al. (16) , which allowed us to use lower concentrations of reference strains, ensuring widely separated or single plaques. Most important, our methods showed sample collections that contained mixtures of new and emerging strains and variants based on ompA and 16S rRNA sequences.
The most remarkable mixed infection was for reference strain A/SA-1 in which C. abortus was identifi ed. C. abortus was not a likely contaminant because A/SA-1 was an original isolate. PCR of another seed stock of A/SA-1 was positive for C. abortus, and C. abortus had not previously been propagated in our laboratory. The original sample was obtained from the conjunctiva of a trachoma patient in Saudi Arabia in 1957. This fi nding was unexpected because C. abortus has not been described among trachoma-endemic populations. Although C. abortus may be responsible for zoonoses in pregnant women, it resides in a unique niche, the placenta, compared with C. trachomatis (26) . Thus, an explanation for our fi ndings is that C. abortus is now capable of crossing species or niche barriers. Indeed, we recently identifi ed mixed conjunctival infections with C. trachomatis, Chlamydophila psittaci, and/or C. pneumoniae in 35% of infected persons residing in a trachoma-endemic region of Nepal (27) . The fi ndings were statistically Figure 3 . Photographs of light and fl uorescent microscopy showing the shotgun cell culture harvest method for isolating clonal populations of clinically persistant strains. A) 1 well in a 6-well plate after harvesting 10 random areas using sterile pipettes; no plaques could be visualized in any well unlike the situation for the reference strains in Figure 2 . B) The same well before harvesting infected areas (magnifi cation ×100). C) Light microscopy view of an area with infected cells containing small inclusion bodies after agarose overlays had been removed (magnifi cation ×400). D) Fluorescent microscopy view of the same fi eld as in C (magnifi cation ×400); infected cells were stained with Chlamydia trachomatis-specifi c lipopolysaccharide antibodies. Arrows denote small fl uorescing inclusion bodies within the cell cytoplasm.
unlikely to have occurred by chance. Additionally, infection with C. pneumoniae or C. psittaci was signifi cantly associated with trachomatous infl ammation, a precursor for scarring. With mounting evidence for widespread interstrain recombination among intracellular bacteria such as Chlamydiaceae (8, 10, (21) (22) (23) 28) , the A/SA1 coinfection with C. abortus along with those described above are likely the tip of the iceberg in terms of the prevalence of mixed Chlamydiaceae infections and the possibility for recombination that may result in diverged tissue tropism (21, 23) . We are currently examining samples from other trachoma-endemic populations for coinfection with C. abortus and other Chlamydiaceae species.
Reference strain Ba/Apache-2 also comprised clonal populations of 3 previously unrecognized ompA genotypes, Ba 1 , Ba 2 and Ba 3 , that were distinct from publicly available Ba ompA sequences (6, 7, 29) . The C662T mutation among our clones encoded a nonsynonymous P221L substitution in a constant region (CR) between variable segments (VSs) II and VSIII of MOMP, which contains 5 CRs and 4 VSs. This change from a proline, an imino amino acid with unique "kink," to a nonpolar leucine on CRIII might disrupt the mid-portion ß-strand transmembrane of MOMP (30) (31) (32) . Furthermore, the E225K in Ba 2 occurs in VSIII where the subspecies-specifi c epitope for LGV and A-K strains (32) is located, likely changing polarity of the epitope from a negative to a positive charge. These mutations, then, may lead to adaptive structural and/or functional changes for MOMP.
The presence of mutations in Ba 1 , Ba 2 , and Ba 3 suggests that these have occurred under immune selection in vivo, because growing reference strains in vitro has not shown detectable mutations (3, 14) , although in theory this could occur. On the basis of phylogenetic reconstructions (Figure 4) , the clonal variants likely represent natural diversity arising from the respective parental strain. Also, the ability of Ba strains to either mutate specifi c protein regions or recombine may facilitate their invasion of other mucosal sites. Urogenital Ba infections do occur, and we have previously described a Ba/D recombinant that was isolated from the genital tract (8) .
Notably, most of the ompA mutations were located within CRs and encoded for nonsynonymous substitutions, the majority of which encoded for nonconservative amino acids with altered properties. For instance, ompA genotype F-III contains a nonconservative G90E substitution. G90E is located in CRII next to VSI, which may decrease membrane hydrophobicity and disrupt the >0.5 nonpolar or hydrophobic index requirement for the MOMP spanning region (32) . In 2 separate studies, we identifi ed F-III variants as statistically signifi cantly associated with pelvic infl ammatory disease (PID) (5, 33) . The F-III mutation may explain, in part, the association with PID. However, additional studies will be required to delineate these associations. In our experimentally mixed infections, recovery of separate clones of D/UW-3 and E/Bour, and of clinical G and F validated each assay ( Table 1 ). The greater number of clones for D/UW-3 (52%) than for E/Bour (36%), and for G (92.31%) than for F (7.69%) might indicate different growth rates and timelines for plaque formation and characteristics of each strain (15, 16) . It is also possible that 1 strain produces byproducts of growth that are inhibitory for coinfecting strains. Nevertheless, these data emphasize the importance of selecting multiple wells of low inocula for plaque or shotgun harvests to identify all strains that are present. Additionally, mixed infections may occur where some strains cause plaque formation and others do not, which stresses the importance of the shotgun harvest even when the morphologic features of plaque are present.
In the present study, we analyzed clones by sequencing ompA, the plasmid, and 16S rRNA to enhance strain categorization. The plasmid was evaluated because its absence has been reported to correlate with reduced or no plaque formation (34) . However, all of our clones contained the plasmid, which is consistent with other studies (35) (36) (37) . The lack of classic plaque formation for clinical isolates likely stems from their slow growth and lack of adaptation to conventional cell culture. This was borne out by their slow growth in shell vials and fl asks, experiments which were performed separately from the plaque assay. Clinical strains may exit the cell without cellular disruption, facilitating subsequent rounds of infection and lack of plaque formation. Beatty recently showed,that EBs could be released without lysis and also be retained by host cells (38) . However, our clinical H formed plaques similar in morphology to reference strains. The presence of a complete toxin gene, as in H/UW-4 and J/UW-36 (39) , may have contributed to clinical H plaque formation. H/UW-4 has been shown to produce more cytotoxicity than D/UW-3, which contains a partial toxin gene, and C. muridanum, which contains a full-length gene (40) . Although all 19 reference strains formed classic plaques morphology, some have no toxin (LGV strains) or a partial gene, which suggests that plaque formation refl ects adaptation to culture that has occurred over decades instead of the effects of the toxin. Further experiments will be required to determine the genetic factors involved in plaque formation.
